Search Results
Results found for "John Teye Azietaku"
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
This Week’s Highlights: Congrats to: John Teye Azietaku , our great contributor, for his article Class
- 📰 GPCR Weekly News, June 10 to 16, 2024
John Teye Azietaku for his contributor article on Unveiling GPCR Priming: The Hidden Synergy in Cellular Join us in vibrant Mexico City from October 23 to 25, 2024, for this key event in adhesion GPCR Biology Science Post-Doctoral Fellow—Pharmacology/Cell Biology/Biochemistry Post Doctoral Fellow Postdoc Position Join
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
This Week’s Highlights: Congrats to: John Teye Azietaku , our great contributor, for his article Class
- 📰 GPCR Weekly News, May 13 to 19, 2024
This week's highlight includes congrats to: John Teye Azietaku for his first contributor article on Illuminating - Global Research Technologies Novo Nordisk Scientist I - Global Research Technologies Novo Nordisk Join
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John
- Join Us Today!
Join the #GPCR movement by becoming a site member for FREE!
- Join Us Now!
Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr
- Dr. GPCR and Eurofins DiscoverX Join Forces to Accelerate GPCR Drug Discovery
Boston, MA and San Diego, CA — [February 18, 2026] — Dr. GPCR , the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. This partnership is designed to support the GPCR research community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident decision-making across the discovery and development continuum. Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most comprehensive GPCR assay portfolios, encompassing over 90% of the human GPCRome with assays for human receptors, species orthologs, and orphan receptors across various cellular backgrounds. Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical and biotechnology companies worldwide. Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification and validation to high-throughput screening (HTS), lead optimization, safety assessment, and regulatory-compliant potency testing. These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed publications and billions of screened data points. “Eurofins DiscoverX is distinguished by its deep GPCR expertise and close collaboration with customers,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR . “They offer more than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR research with confidence.” “Dr. GPCR plays a critical role in educating and connecting the global GPCR community,” said Geoffrey Donsimoni, GPCR Marketing Director at Eurofins DiscoverX . “Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world applications that help researchers fully leverage GPCR assay technologies across discovery and development.” Together, Dr. GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design and data interpretation. To explore Eurofins DiscoverX GPCR assay solutions and curated resources, visit: https://www.ecosystem.drgpcr.com/eurofins-discoverx To learn more about Dr. GPCR’s educational programs and global GPCR community, visit https://www.ecosystem.drgpcr.com About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem, Dr. GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery. About Eurofins DiscoverX Eurofins DiscoverX is a global leader in GPCR cell-based assay technologies, providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development. With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.
- Join the #GPCR movement today!
🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025] — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. As a Dr. GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr. GPCR Newsletter , University Courses , and Podcast , as well as the searchable Dr. GPCR Ecosystem Directory —a centralized hub for tools, training, and technology. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,” said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,” said Wilson Gomes , CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,” added Dr. Maria Majellaro , CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit www.celtarys.com . For access to Dr. GPCR’s global network, educational content, and discovery tools, visit ecosystem.drgpcr.com . ___________ About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 160 podcast episodes, live and on-demand educational programs, and a dynamic partner ecosystem, Dr. GPCR empowers scientists and companies advancing receptor biology and drug discovery. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development of optimal chemical tools for drug discovery. Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development, screening, and live-cell imaging.
- Join Dr. GPCR Summit 2022 in 3 simple steps!
Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers.
- Carola Weiss joins InterAx Biotech AG as VP Business Development
February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer,
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
AZIETAKU, J.T., Profiling Glucagon-Like Peptide -1 Receptor Transducer Coupling, Signalling and Biased
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
As a lab technician at Johns Hopkins, he was fascinated by science but also grounded in real-life responsibilities
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
It was great to bring everyone together and also welcome new member John Parkinson."
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
His new obsession led him to Johns Hopkins, where he worked in the lab of Dr.
- 📰 GPCR Weekly News, January 8 to 14, 2024
GPCR University February 8 - 29: Join Dr. GPCR University's live course with Dr. Terry Kenakin. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join us at the Endocrine Metabolic GPCRs event on April MolFlux: Empowering the ML Community in Molecular Predictive Modelling NanoImaging Services Appoints John
- 🎄 Have Yourself a Merry Little GPCRmas! ❄ Dec 9 - 15, 2024
contributes to inflammatory joint pain Luke A Pattison , Rebecca H Rickman , Graham Ladds , Ewan St John
- 📰 GPCR Weekly News, October 30 to November 4, 2023
fluorescent analogues for real-time binding studies of orphan GPCR GPR3: Save the dates: November 17: Join Receives R&D Achievement of the Year Award for GPCR Research Bryan Roth, Natural Products, and the John
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Legacy of Schild Analysis Schild analysis was born from an elegantly simple equation published by Sir John
- 📰 GPCR Weekly News, April 29 to May 5, 2024
Join us in this wonderful episode to meet the team of volunteers behind the work you see. We also have some important announcements in today’s episode, so join us in this celebration and be the If you aren't joining us this time, stay tuned for more Dr. GPCR University content coming soon.
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
Premium Members get a 50%+ discount when they join Terry’s Corner. 🚨 First-ever Live AMA with Dr. Join Terry's Corner Today ➤ Celtarys Research – Confocal Imaging That Preserves GPCR Function Confocal He joins Dr. . 🎥 Plus, join us at the GPCR Track, GPCR Happy Hour, and more! 🚀 Join Premium Today ➤
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Starting From Zero: Growing With a Mentor When Alessandro joined Prof. Join the GPCR scientist network and connect with peers shaping the next wave of discovery. ________ Keyword
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
Help grow the GPCR community by joining the Dr. GPCR affiliate program. Join the Affiliate Program Your Shortcut to Dr.
- 📰 GPCR Weekly News, April 1 to 7, 2024
Join our upcoming Dr. GPCR University hands-on workshop with Dr. GPCR Symposia Join us on June 7th for our next symposium on Structural and Molecular Insights into GPCR GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs Domain Therapeutics to participate at premier investor and healthcare conferences Montana Molecular is joining disorder, pharmacology Research Fellow Postdoctoral Fellow – Molecular Pharmacology of Feeding Behavior Join
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
Taste Receptors, and Context-Dependent Signaling In this episode of the DrGPCR Podcast, Keyvan Sedaghat joins Scientists living and working in developing countries can join for $25 per year — permanently set to Join Dr. GPCR Premium — Build Your Structured Advantage ➤
- 📰 GPCR Weekly News, March 4 to 10, 2024
If you are joining from anywhere else in the world, please plan accordingly. If you're eager to attend, join our waitlist for updates on its return later this year. GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs networks and whole-genome SNP-based analysis Industry News Boehringer Ingelheim and Sosei Heptares join - Single-molecule Imaging Center Scientific Assistant Postdoctoral Fellowship- Mechanistic Biology Join
- 📰 GPCR Weekly News, February 12 to 18, 2024
You can still join this waitlist and be the first to know when the live course is offered later this GPCR Volunteers Join our dynamic team as a volunteer! You'll share your contributor articles with the community, stay updated with GPCR literature, join a GPCR Partnered Events March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug Discovery Summit Join us at the 3rd April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join Dr. GPCR founder Dr.
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
Join Terry’s Corner and stay updated on the latest in GPCR research—delivered in a format that’s as approachable



















